27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Vascular Biogenics (NASDAQ: VBLT) announces its next round of earnings this Monday, November 16. Here is Benzinga's everything-that-matters guide for this Monday's Q3 earnings announcement.
Net Income, Earnings, And Earnings Per Share
Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.
Earnings And Revenue
Sell-side analysts are expecting Vascular Biogenics's loss per share to be near $0.13 on sales of $170.00 thousand. In the same quarter last year, Vascular Biogenics announced EPS of $0.14 on revenue of $79.00 thousand.
What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?
Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.
If the company were to report earnings in line when it publishes results Monday, quarterly profit would be up 7.14%. Revenue would be up 115.19% from the same quarter last year. Vascular Biogenics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q2 2020 | Q1 2020 | Q4 2020 | Q3 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.14 | -0.17 | -0.13 | -0.14 |
| EPS Actual | -0.14 | -0.15 | -0.16 | -0.14 |
| Revenue Estimate | 150.00 K | 160.00 K | 110.00 K | 120.00 K |
| Revenue Actual | 158.00 K | 366.00 K | 126.00 K | 79.00 K |
Stock Performance
Shares of Vascular Biogenics were trading at $1.12 as of November 12. Over the last 52-week period, shares are down 2.99%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Do not be surprised to see the stock move on comments made during its conference call. Vascular Biogenics is scheduled to hold the call at 08:30:00 ET and can be accessed here.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!